A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma

What is this summary about? This summary describes the final analysis of the GRIFFIN study. In this study, participants were newly diagnosed with a type of blood and bone marrow cancer called multiple myeloma, had never received any treatment, and were able to undergo an autologous stem cell transplant. The GRIFFIN study looked at adding the drug daratumumab (D) to a combination of standard treatments called RVd (lenalidomide [R], bortezomib [V], and dexamethasone [d]) during the treatment phases induction and consolidation, followed by daratumumab and lenalidomide (D-R) maintenance. Participants also received an autologous stem cell transplant to further help reduce multiple myeloma. The GRIFFIN study looked at whether D-RVd followed by D-R maintenance was better at killing multiple myeloma cells compared with RVd on its own followed by R maintenance on its own, and if treatments were safe. This summary also describes results from 2 other GRIFFIN publications: one that looked at participants with certain multiple myeloma characteristics or demographic factors that are associated with worse outcomes, and another that looked at how treatments impacted the participants' quality of life. What were the results? At the time of the final analysis of GRIFFIN, participants who were treated with D-RVd followed by D-R maintenance had very low (undetectable) levels of multiple myeloma cells and multiple myeloma markers (biological signs) and were more likely to be alive without the multiple myeloma getting worse or coming back compared with participants who received standard RVd treatment followed by R maintenance. There was also a pattern of similar benefits achieved by participants who were at risk for worse outcomes. Additionally, participants who received D-RVd treatment followed by D-R maintenance reported less pain, less fatigue (extreme tiredness), and greater improvements in their ability to conduct daily physical activities. While some side effects (unwanted or unexpected effects of treatment) were higher with D-RVd, side effects in both groups were as expected, and adding daratumumab did not reduce a participant's ability to handle treatment. What do the results of the study mean? Results of the GRIFFIN study showed that D-RVd treatment followed by D-R maintenance was better at treating multiple myeloma than the standard treatment of RVd followed by R maintenance in adults with a new diagnosis of multiple myeloma who were able to receive an autologous stem cell transplant, with no unexpected side effects of treatment. Clinical Trial Registration: NCT02874742 (GRIFFIN) (ClinicalTrials.gov) Link to original article here Link to original article here Link to original article here

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2024-10-25
DOI
https://doi.org/10.1080/14796694.2024.2408909
Citations
2
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.91

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma

Sarah A. Holstein, Luciano J. Costa, Saad Z. Usmani, Andrew J. Cowan et al.
2 citations
Future Oncology
Multiple Myeloma Research and Treatments
0.91
article

A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma

Sarah A. Holstein, Luciano J. Costa, Saad Z. Usmani, Andrew J. Cowan, Naresh Bumma, Rebecca Silbermann, Robert Zygmunt Orlowski, Larry D. Anderson, Nitya Nathwani, Caitlin Costello, Paul Gerard Guy Richardson, Huiling Pei, Brandi Reeves, Jacob P. Laubach, Kenneth H. Shain, Douglas W. Sborov, Nina Shah, Andrzej J. Jakubowiak, Yvonne A. Efebera, Annelore Cortoos, Katharine S. Gries, Shira Naomi Dinner, Peter Michael Voorhees, Jonathan L. Kaufman, Tanya M. Wildes, Sharmila Patel, Cesar Rodriguez, Thomas S. Lin
article en
2 citations

Abstract

What is this summary about? This summary describes the final analysis of the GRIFFIN study. In this study, participants were newly diagnosed with a type of blood and bone marrow cancer called multiple myeloma, had never received any treatment, and were able to undergo an autologous stem cell transplant. The GRIFFIN study looked at adding the drug daratumumab (D) to a combination of standard treatments called RVd (lenalidomide [R], bortezomib [V], and dexamethasone [d]) during the treatment phases induction and consolidation, followed by daratumumab and lenalidomide (D-R) maintenance. Participants also received an autologous stem cell transplant to further help reduce multiple myeloma. The GRIFFIN study looked at whether D-RVd followed by D-R maintenance was better at killing multiple myeloma cells compared with RVd on its own followed by R maintenance on its own, and if treatments were safe. This summary also describes results from 2 other GRIFFIN publications: one that looked at participants with certain multiple myeloma characteristics or demographic factors that are associated with worse outcomes, and another that looked at how treatments impacted the participants' quality of life. What were the results? At the time of the final analysis of GRIFFIN, participants who were treated with D-RVd followed by D-R maintenance had very low (undetectable) levels of multiple myeloma cells and multiple myeloma markers (biological signs) and were more likely to be alive without the multiple myeloma getting worse or coming back compared with participants who received standard RVd treatment followed by R maintenance. There was also a pattern of similar benefits achieved by participants who were at risk for worse outcomes. Additionally, participants who received D-RVd treatment followed by D-R maintenance reported less pain, less fatigue (extreme tiredness), and greater improvements in their ability to conduct daily physical activities. While some side effects (unwanted or unexpected effects of treatment) were higher with D-RVd, side effects in both groups were as expected, and adding daratumumab did not reduce a participant's ability to handle treatment. What do the results of the study mean? Results of the GRIFFIN study showed that D-RVd treatment followed by D-R maintenance was better at treating multiple myeloma than the standard treatment of RVd followed by R maintenance in adults with a new diagnosis of multiple myeloma who were able to receive an autologous stem cell transplant, with no unexpected side effects of treatment. Clinical Trial Registration: NCT02874742 (GRIFFIN) (ClinicalTrials.gov) Link to original article here Link to original article here Link to original article here

Future OncologyVol. 21(1)
Northwestern University (US), University of North Carolina at Chapel Hill (US), OhioHealth (US), NHS Blood and Transplant (GB), Johnson & Johnson (United States) (US), Memorial Sloan Kettering Cancer Center (US), University of Alabama at Birmingham Hospital (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Janssen (Belgium) (BE), Emory University (US), Oregon Health & Science University (US), University of California, San Francisco (US), University of Washington (US), University of Utah (US), Huntsman Cancer Institute (US), Cancer Institute (WIA) (IN), University of Washington Medical Center (US), Multiple Myeloma Research Foundation (US), Moffitt Cancer Center (US), University of California San Diego (US), University of Chicago Medical Center (US), Southwestern Medical Center (US), Piedmont Cancer Institute (US), Levine Cancer Institute (US), Amyloidosis Foundation (US), Johnson & Johnson (Sweden) (SE), City of Hope (US), CancerCare (US), Palmetto Hematology Oncology (US), Myeloma UK (GB), Dana-Farber/Harvard Cancer Center (US), Hematology Oncology Associates (US), Janssen (United States) (US), Southwestern Medical Center (US), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Moores Cancer Center, Winship Cancer Institute, OHSU Knight Cancer Institute, Harold C. Simmons Comprehensive Cancer Center, Janssen Scientific Affairs (United States), Wake Forest University (US), The Ohio State University (US), University of Nebraska Medical Center (US), The University of Texas Southwestern Medical Center (US), Icahn School of Medicine at Mount Sinai (US)
Amgen, Bristol-Myers Squibb, Sanofi, Celgene, Incyte, Genentech
Openalex Percentile: Top 22%
Multiple Myeloma Research and Treatments
0.91
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.